Search Within

Connie Wing-Ching Lee Batlevi

  1. "Advanced Practice Providers"
Formats
  1. Meeting Abstract (20)
  2. Journal Article (5)
  3. Research Letter (2)
Groups
  1. Advanced Practice Providers (27)
  2. Center for Hematologic Malignancies (27)
  3. Department of Medicine (27)
  4. Hematologic Malignancies, Division of (27)
  5. Lymphoma (27)
  6. Survivorship Research (25)

More Groups

People
  1. Maria Palomba (23)
  2. Gunjan Shah (18)
  3. Bianca Santomasso (15)
  4. Craig Sauter (15)
  5. Miguel-Angel Perales (15)
  6. Sergio Giralt (15)

More People

Years
  1. 2023 (1)
  2. 2022 (1)
  3. 2021 (7)
  4. 2020 (6)
  5. 2019 (9)
  6. 2018 (3)
Publications
  1. Blood (13)
  2. Blood Advances (4)
  3. Biology of Blood and Marrow Transplantation (2)
  4. Hematological Oncology (2)
  5. Bone Marrow Transplantation (1)
  6. Haematologica (1)

More Publications

Publishers
  1. American Society of Hematology (17)
  2. Elsevier Inc. (3)
  3. Elsevier Science, Inc. (2)
  4. Wiley Blackwell (2)
  5. American Society of Clinical Oncology (1)
  6. Ferrata Storti Foundation (1)

More Publishers

Results (27)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Hematological count recovery in patients undergoing treatment with chimeric antigen receptor T cells (CAR T)
    Meeting Abstract

    Jain, T.; Knezevic, A.; Pennisi, M.; Ruiz, J. D.; Devlin, S. M.; Maloy, M. A.; Halton, E.; Diamonte, C.; Scordo, M.; Sauter, C. S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Thirty day resource utilization after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J.; Sauter, C. S.; Duck, E.; Halton, E.; Batlevi, C. W.; Palomba, M. L.; Younes, A.; Geyer, M. B.; Smith, E.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Resource utilization within 30 days of car T cells for hematologic malignancies
    Meeting Abstract

    Shah, G.; Park, J.; Sauter, C.; Duck, E.; Halton, E.; Batlevi, C.; Palomba, M. L.; Younes, A.; Geyer, M.; Smith, E.; more...
    Value in Health (2019)

    Fulltext@MSK | Save
  • Phase I clinical trial of CD19‐targeted 19‐28z/4‐1BBL "armored" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter transformation
    Meeting Abstract

    Batlevi, C. L.; Palomba, M. L.; Park, J.; Mead, E.; Santomasso, B.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R.; Yang, J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Resource utilization early after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J. H.; Sauter, C. S.; Duck, E.; Halton, E.; Palomba, M. L.; Batlevi, C. L.; Younes, A.; Geyer, M. B.; Smith, E. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • A phase I first-in-human clinical trial of CD19-targeted 19-28z/4-1BBL "armored" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter's transformation
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Batlevi, C. L.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R. R.; Bernal, Y.; Hall, M.; Pineda, J.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Initial results of a phase II study of sequential chemotherapy and lenalidomide followed by rituximab and lenalidomide maintenance for untreated mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Zelenetz, A. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Laraque, L.; more...
    Blood (2018)

    Fulltext@MSK | Save